OAC
SPRO icon

OMERS Administration Corp’s Spero Therapeutics SPRO Stock Holding History

OMERS Administration Corp’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-39,400
Closed -$92.2K – 1118
2026
Q1 		$92.2K Sell
39,400
-91,727
-70% -$218K ﹤0.01% 1026
2025
Q4 		$306K Buy
+131,127
New +$304K ﹤0.01% 812

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

OMERS Administration Corp's SPRO Position: Q2 2026 in Review

OMERS Administration Corp sold out of Spero Therapeutics (SPRO) in Q2 2026, closing a stake of 39,400 shares — an estimated $92.2K sold.

OMERS Administration Corp first reported a position in SPRO in Q4 2025 and held it in 2 quarters. The position peaked at $306K in Q4 2025. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • OMERS Administration Corp reported no remaining Spero Therapeutics position as of Q2 2026 after selling out during the quarter.
  • OMERS Administration Corp sold 39,400 Spero Therapeutics shares in Q2 2026, an estimated $92.2K.
  • OMERS Administration Corp first reported a position in Spero Therapeutics in Q4 2025 and held it in 2 quarters.
  • OMERS Administration Corp's Spero Therapeutics position peaked at $306K in Q4 2025.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on OMERS Administration Corp's 13F filing for Q2 2026, filed 13 Aug 2026.